Grace M. Lee

Grace M. Lee

Auto-generated profile, based on publicly available information

Grace M. Lee

Division of Hematology, Department of Medicine Duke University Medical Center Durham North Carolina USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2013 in Hematology-American Society Hematology Education Program
Verified
Journal Article
Open access
PDF file
GLGrace M. Lee
Grace M. Lee
GAGowthami M. Arepally
Gowthami M. Arepally
Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder caused by antibodies that recognize complexes of platelet factor 4 (PF4) and heparin. HIT is frequently considered in the differential diagnosis of thrombocytopenia occurring in patients on heparin therapy. HIT is a challenging diagnosis because of routine heparin use in hospitalized patients, the common occurrence of thrombocytopenia, and high rates of anti-PF4/heparin seroconversions in patients treated with heparin. Our diagnostic approach to HIT is presented here, underscoring critical elements of clinical and laboratory evaluation.

6 December 2018 in Blood
Verified
Journal Article
Closed access
PDF file
SKSanjay Khandelwal
Sanjay Khandelwal
JRJoann Ravi
Joann Ravi
LRLubica Rauova
Lubica Rauova
AJAlexandra Johnson
Alexandra Johnson
GLGrace M. Lee
Grace M. Lee
GAGowthami M. Arepally
Gowthami M. Arepally
The mechanisms by which exposure to heparin initiates antibody responses in many, if not most, recipients are poorly understood. We recently demonstrated that antigenic platelet factor 4 (PF4)/heparin complexes activate complement in plasma and bind to B cells. Here, we describe how this process is initiated. We observed wide stable variation in complement activation when PF4/heparin was added to plasma of healthy donors, indicating a responder “phenotype” (high, intermediate, or low). Proteomic analysis of plasma from these healthy donors showed a strong correlation between complement activation and plasma immunoglobulin M (IgM) levels (r = 0.898; P < .005), but not other Ig isotypes. Complement activation response to PF4/heparin in plasma displaying the low donor phenotype was enhanced by adding pooled IgM from healthy donors, but not monoclonal IgM. Depletion of IgM from plasma abrogated C3c generation by PF4/heparin. The complement-activating features of IgM are likely mediated by nonimmune, or natural, IgM, as cord blood and a monoclonal polyreactive IgM generate C3c in the presence of PF4/heparin. IgM facilitates complement and antigen deposition on B cells in vitro and in patients receiving heparin. Anti-C1q antibody prevents IgM-mediated complement activation by PF4/heparin complexes, indicating classical pathway involvement. These studies demonstrate that variability in plasma IgM levels correlates with functional complement responses to PF4/heparin. Polyreactive IgM binds PF4/heparin, triggers activation of the classical complement pathway, and promotes antigen and complement deposition on B cells. These studies provide new insights into the evolution of the heparin-induced thrombocytopenia immune response and may provide a biomarker of risk.

25 November 2021 in Blood
Verified
Journal Article
Open access
PDF file
SKSanjay Khandelwal
Sanjay Khandelwal
ABAyiesha Barnes
Ayiesha Barnes
LRLubica Rauova
Lubica Rauova
ASAmrita Sarkar
Amrita Sarkar
ARAnn H. Rux
Ann H. Rux
DCDouglas B. Cines
Douglas B. Cines
Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder mediated by ultra-large immune complexes (ULICs) containing immunoglobulin G (IgG) antibodies to a multivalent antigen composed of platelet factor 4 and heparin. The limitations of current antithrombotic therapy in HIT supports the need to identify additional pathways that may be targets for therapy. Activation of FcγRIIA by HIT ULICs initiates diverse procoagulant cellular effector functions. HIT ULICs are also known to activate complement, but the contribution of this pathway to the pathogenesis of HIT has not been studied in detail. We observed that HIT ULICs physically interact with C1q in buffer and plasma, activate complement via the classical pathway, promote codeposition of IgG and C3 complement fragments (C3c) on neutrophil and monocyte cell surfaces. Complement activation by ULICs, in turn, facilitates FcγR-independent monocyte tissue factor expression, enhances IgG binding to the cell surface FcγRs, and promotes platelet adhesion to injured endothelium. Inhibition of the proximal, but not terminal, steps in the complement pathway abrogates monocyte tissue factor expression by HIT ULICs. Together, these studies suggest a major role for complement activation in regulating Fc-dependent effector functions of HIT ULICs, identify potential non-anticoagulant targets for therapy, and provide insights into the broader roles of complement in immune complex–mediated thrombotic disorders.

1 June 2013 in Hematology/Oncology Clinics of North America
Verified
Journal Article
Closed access
GLGrace M. Lee
Grace M. Lee
GAGowthami M. Arepally
Gowthami M. Arepally

2 August 2022 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
SMStacey A Maskarinec
Stacey A Maskarinec
MMMargaret McKelvy
Margaret McKelvy
KBKimberly Boyle
Kimberly Boyle
HHHalie Hotchkiss
Halie Hotchkiss
MDMadelaine E Duarte
Madelaine E Duarte
GLGrace M Lee
Grace M Lee

25 September 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
MDMadelaine Duarte
Madelaine Duarte
MKMaragatha Kuchibhatla
Maragatha Kuchibhatla
SKSanjay Khandelwal
Sanjay Khandelwal
GAGowthami M. Arepally
Gowthami M. Arepally
GLGrace M. Lee
Grace M. Lee
Key Points: In a whole blood assay, ICs cause neutrophil activation and degranulation. Individuals have a fixed susceptibility to neutrophil activation by ICs.